Wayne
The rrms trial with 2102
Was run at 600mg for the first two weeks
3x 200mg doses
Then reduced to 400mg 2x200mg doses for the next seven weeks
This is why I think it's great news that in the prelim 25mg appears to have achieved it's goal in reducing CD49d as in it was moving in a downwards trend untill the trial ceased at which time the numbers began to increase once more
So scientifically I would imagine moving forwards it would be a matter of getting the correct dosing to avoid the low platlet count
which really bodes well for the drug in that it could well be a drug that could be used dosed correctly on a permanent basis without danger of serious side effects
and therefore reducing inflamation whilst other drugs can make a clean attempt to either replace or repair dystrophin without hinderance in these boys
Very exciting time I believe
Sp wise just the first wave out of a set on its way
See how we go
ANP Price at posting:
9.4¢ Sentiment: Buy Disclosure: Held
(20min delay)
